Research Papers:

The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia

Sara Galimberti _, Cristina Bucelli, Elena Arrigoni, Claudia Baratè, Susanna Grassi, Federica Ricci, Francesca Guerrini, Elena Ciabatti, Carmen Fava, Antonio D’Avolio, Giulia Fontanelli, Giovanna Rege Cambrin, Alessandro Isidori, Federica Loscocco, Giovanni Caocci, Marianna Greco, Monica Bocchia, Lara Aprile, Antonella Gozzini, Barbara Scappini, Daniele Cattaneo, Anna Rita Scortechini, Giorgio La Nasa, Alberto Bosi, Pietro Leoni, Romano Danesi, Giuseppe Saglio, Giuseppe Visani, Agostino Cortelezzi, Mario Petrini, Alessandra Iurlo and Antonello Di Paolo

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:88021-88033. https://doi.org/10.18632/oncotarget.21406

Metrics: PDF 2067 views  |   HTML 2556 views  |   ?  


Sara Galimberti1, Cristina Bucelli2, Elena Arrigoni3, Claudia Baratè1, Susanna Grassi1,4, Federica Ricci1, Francesca Guerrini1, Elena Ciabatti1, Carmen Fava5, Antonio D’Avolio6, Giulia Fontanelli1, Giovanna Rege Cambrin7, Alessandro Isidori8, Federica Loscocco8, Giovanni Caocci9, Marianna Greco9, Monica Bocchia10, Lara Aprile10, Antonella Gozzini11, Barbara Scappini11, Daniele Cattaneo2, Anna Rita Scortechini12, Giorgio La Nasa9, Alberto Bosi11, Pietro Leoni12, Romano Danesi3, Giuseppe Saglio5, Giuseppe Visani8, Agostino Cortelezzi2, Mario Petrini1, Alessandra Iurlo2 and Antonello Di Paolo3

1Department of Clinical and Experimental Medicine, Section of Hematology, University of Pisa, Pisa, Italy

2Oncohematology Division, IRCCS Ca’ Granda, Maggiore Policlinico Hospital Foundation, University of Milan, Milano, Italy

3Department of Clinical and Experimental Medicine, Section of Pharmacology, University of Pisa, Pisa, Italy

4GeNOMEC, University of Siena, Siena, Italy

5Hematology Division, Ospedale Mauriziano, Torino, Italy

6Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Torino, Torino, Italy

7Department of Clinical and Biological Sciences, University of Torino, AOU San Luigi Gonzaga, Torino, Italy

8Hematology and Stem Cell Transplant Center, San Salvatore Hospital, Pesaro, Italy

9Department of Medical Sciences, University of Cagliari, Cagliari, Italy

10Division of Hematology, Ospedale Le Scotte, University of Siena, Siena, Italy

11Division of Hematology, AOU Careggi, University of Florence, Firenze, Italy

12Division of Hematology, Marche Polytechnic University, Ancona, Italy

Correspondence to:

Sara Galimberti, email: [email protected]

Keywords: nilotinib, ABC transporters, ABCB1, hOCT1, early molecular response

Received: June 24, 2017    Accepted: August 29, 2017    Published: September 30, 2017


First-line nilotinib in chronic myeloid leukemia is more effective than imatinib to achieve early and deep molecular responses, despite poor tolerability or failure observed in one-third of patients. The toxicity and efficacy of tyrosine kinase inhibitors might depend on the activity of transmembrane transporters. However, the impact of transporters genes polymorphisms in nilotinib setting is still debated. We investigated the possible correlation between single nucleotide polymorphisms of hOCT1 (rs683369 [c.480C>G]) and ABCB1 (rs1128503 [c.1236C>T], rs2032582 [c.2677G>T/A], rs1045642 [c.3435C>T]) and nilotinib efficacy and toxicity in a cohort of 78 patients affected by chronic myeloid leukemia in the context of current clinical practice. The early molecular response was achieved by 81% of patients while 64% of them attained deep molecular response (median time, 26 months). The 36-month event-free survival was 86%, whereas 58% of patients experienced toxicities. Interestingly, hOCT1 and ABCB1 polymorphisms alone or in combination did not influence event-free survival or the adverse events rate. Therefore, in contrast to data obtained in patients treated with imatinib, hOCT1 and ABCB1 polymorphisms do not impact on nilotinib efficacy or toxicity. This could be relevant in the choice of the first-line therapy: patients with polymorphisms that negatively condition imatinib efficacy might thus receive nilotinib as first-line therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21406